Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Cloudbreak Therapeutics operates a capital efficient business model based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC)Phase II clinical trials and to out-license global rights for Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.

Biotechnology

Health Care

Cloudbreak Pharma

Jinsong Ni

Elizabeth Capan

W. Ken Fang

Greg Brooks

Rong Yang

Van Dinh

Abu Abraham

Rebecca Chan

Leadership Team

Research and Development

Teams at Cloudbreak Pharma

Leadership Team

Research and Development